Finally, the results of the ROC curve analyses showed that the differential expression of NORAD has an excellent potential to discriminate Basal-like tumor samples (n = 190) from non-tumor samples (n = 113) (88.5% sensitivity, 72.11% specificity, AUC = 0.8496, CI: 0.80–0.89, p < 0.001), suggesting its potential as a biomarker in Basal-like patients. This evidence concerns the gene NORAD and neoplasm.